FORM6-K

REPORT OF FOREIGN PRIV ATE ISSUER PURSUANT TO RULE 13a-16 OR lSd-16 OF THE SECURITIES EXCHANGE ACT OF 1934

For the month ofMay 2023

Commission File Number: 001-36187

EVOGENELm.

(Translation ofRegistrant's Name into English)

13 Gad Feinstein Street, Park Rehovot, Rehovot P.O.B 4173, Ness Ziona, 7414002, Israel (Address ofprincipal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover ofFonn 20-F or Fonn 40-F.

Form20-F 181 Form40-F D

Indicate by check mark ifthe registrant is submitting the Fonn 6-K in paper as permitted by Regulation S-T Rule IOl(b)(l): __

Indicate by check mark ifthe registrant is submitting the Fonn 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): __

On May 9, 2023 Evogene Ltd., or Evogene, announced that its Ag-Seed Division was awarded a prestigious Horizon grant of €1.2 million to develop oil-seed crops with high C02 assimilation and drought tolerance. A copy of the press release is fumished as Exhibit 99.1 to this Report ofForeign Private Issuer on Fonn 6-K, or this Fonn 6-K.

The contents of Exhibit 99.1 to this Fonn 6-K, excluding the quotes in fifth, sixth and seventh paragraphs, are incorporated by reference into the registration statements on Fonn F-3 (File No. 333-253300) and on Fonn S-8 (File Nos. 333-193788, 333-201443, 333-203856 and 333-259215) ofEvogene, filed with the Securities and Exchange Commission, to be a part thereoffrom the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or fumished.

Signature

Pursuant to the requirements ofthe Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalfby the undersigned, thereunto duly authorized.

EVOGENE Lm. (Registrant)

Date: May 9, 2023 By: /s/ Yaron Eldad YaronEldad ChiefFinancial Officer

Evogene Ag-Seed Division Awarded Prestigious €1.2M Horizon Grant to Develop Oil-Seed Crops with High C02 Assimilation & Drought Tolerance

The grant under the EU Horizon Program was approved fol/owing the successful proofof concept from the previous program launched in 2016

Rehovot, Israel - May 9, 2023 - The Ag-Seed Division of Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN)("Evogene"), a leading computational biology company targeting to revolutionize lifescience product discovery and development across multiple market segments has announced that it has been granted a prestigious EU Horizon grant of€1.2 million, to support the creation ofoilseed crops that have high carbon-dioxide assimilation and enhanced drought tolerance. The project, Crop4Clima, has an overall budget of €2.5 million and is expected to be executed over 32 months. This grant follows the successful completion of the FutureAgriculture Consortium's proof-of-concept in 2021 , which demonstrated the potential for increased agricultural productivity and environmental sustainability.

The program's goal is to develop crops, focusing f1rst on canola and rapeseed seeds, with the ability to assimilate 60% more carbon dioxide from the air while requiring 20% less water intake when compared to crops grown under standard agricultural practices in order to support sustainability goals. It supports efforts to reduce global warming by using plants with a higher uptake of carbon dioxide accumulation from the atmosphere. 1n addition, it enables the saving of scarce water resources and improved plant tolerance against drought conditions. Furthermore, it is expected that biomass yield per hectare will improve while the plant maintains a high oil content, as demanded by canola-derived products and the biofuel industry. The potential commercial value ofsuch products for the food, animal feed, and sustainable energy industries is significant.

This development follows a successful proof-of-concept, completed in 2021 as part of the FutureAgriculture Consortium funded by the EU Horizon Program. Results showed increased carbondioxide assimilation by plants, combined with improved drought tolerance and plant productivity. These positive results indicated the commercial potential ofincreased agricultural productivity while supporting sustainability goals. They led the Horizon 2020 reviewers to recommend continuing funding the project's development as a significant measure to reduce climate change.

Crop4Clima is part ofHorizon Europe's highly competitive and prestigious EIC Transition program, whose goal is to establish businesses addressing climate challenges and develop resilient and environmentally sustainable crops which can better address climate change. The €1.2 rnillion grant awarded to Evogene will cover Evogene's estimated costs to participate in this program. Other partners in this project include the Max Planck Society, Germany's leading basic research institution, IN Society, an Italian not-for-profit SME that analyzes the impact of emerging technologies on society, andAgrobioinstitute, Agricultural Academy, Sofia, Bulgaria. The program leverages Evogene's Ag-seeds Division's and its partners' innovative synthetic biology technologies while integrating multidisciplinary skills in computational biology, chernistry, microbiology, and plant physiology.

The Max Planck Institute for Terrestrial Microbiology conducts research on the molecular functions of environmental rnicroorganisms and their potential use for synthetic biology. Professor Dr. Tobias Erb, Director of the Department of Biochemistry and Synthetic MetaboHsm at Max Planck, commented, "Our research on basic design principles ofmicrobial metabolism enabled us to engineer improved carbon-dioxide uptake mechanisms. The joint project with Evogene is an important part of our efforts to create a sustainable future with synthetic biology. By engineering novel metabolic pathways, we aim to enable plants to make better use of cellular resources, thus saving fertilizer and water and reducing the release of carbon dioxide in agriculture."

According to Laura Martinelli, CEO of IN Society, "Crop4Clima is a perfect example ofscience translated into socially relevant innovation, as it will enable agriculture to cope with the changing demands of climate change. Since its inception, we have supported this prornising innovation as part ofthe FutureAgriculture project. We are excited to play a key role in this new phase and contribute to its success by perforrning the environmental and economic assessment and facilitating stakeholder adoption ofthe technology."

Eyal Ronen, EVP ofBusiness Development ofEvogene, commented: "We are proud to lead the development ofthese oil-seed crops with uoique characteristics, supporting sustainability goals. The proof of concept is further validated by our consortium winning the prestigious European Horizon grant, whose goal is sustainable agriculture. We are also excited to work in this consortium with the Max Planck Institute for Terrestrial Microbiology, a global scientific leader in environmental and synthetic biology. This win reflects our expertise in synthetic and computational biology, and our ability to develop innovative new products."

Forward Look Statements & Disclabner

This press release contains 'forward-looking statements" relating to future events. These statements may be identified by words such as "may ", "could", "expects ", "hopes" "intends ", ''anticipates ", "plans ", "believes ", ''scheduled", ''estimates ", "demonstrates" or words ofsimilar meaning. For example, Evogene and its subsidiaries are usingforward-looking statements in this press release when it discusses the success ofits development ofoil-seed crops with high carbon-dioxide assimilation and increased drought tolerance. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees offuture performance. Therefore, actual future results, performance, or achievements ofEvogene and its subsidiaries may dijfer materially from what is expressed or implied by suchforward-looking statements due to a variety offactors, many ofwhich are beyond the control ofEvogene and its subsidiaries, including, without limitation, those riskfactors contained in Evogene 's reports filed with the applicable securities authority. ln addition, Evogene and its subsidiaries rely, and expect to continue to rely, on third parties to conduct certain activities, such as their field trials and pre-clinical studies, and if these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, Evogene and its subsidiaries may experience significant delays in the conduct oftheir activities. Evogene and its subsidiaries disclaim any obligation or commitment to update these forward-looking statements to rejlect future events or developments or changes in expectations, estimates, projections and assumptions.

Funded by the European Union. Views and opinions expressed are however those ofthe author(s) only and do not necessarily rejlect those ofthe European Union or EIC 2022 program (the granting authority). Neither the European Union, nor the granting authority, can be held responsible for them.

About Evogene Ltd.

Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN) is a computational biology company leveraging big data and artificial intelligence, aiming to revolutionize tbe development of life-science based products by utilizing cutting-edge technologies to increase tbe probability ofsuccess while reducing development time and cost.

Evogene established tbree unique tech-engines - MicroBoost AI, ChemPass AI and GeneRator AI. Each tech-engine is focused on tbe discovery and development ofproducts based on one of tbe following core components: microbes (MicroBoost AI), small molecules (ChemPass AI), and genetic elements ( GeneRatorAI).

Evogene uses its tech-engines to develop products through strategic partnerships and collaborations, and its five subsidiaries including:

.ו Biomica Ltd. !www bjomjcamed.com) developing and advancing novel microbiome-based therapeutics to treat human disorders powered by MicroBoost AI;
1. Lavie Bio Ltd. (www.lavie-bio.com) developing and commercially advancing, microbiome based ag-biologicals powered by MicroBoost AI;
1. AgPienus Ltd. (www.agplenus.com) -developing next generation ag chemicals for effective and sustainable crop protection powered by ChemPass AI;
1. Canonic Ltd (www.canonicbio.com)--developing) developing medical cannabis products based on decoding plant genetics for optimized therapeutic effect powered by GeneRator AI; and
1. Casterra Ag Ltd. (www.casterra.co}- developing and marketing superior castor seed varieties producing high yield and high-grade oil content, on an industrial scale for the biofuel and other industries powered by GeneRatorAJ.

For more information, please visit

Eyogene Inץestors' Contact;

Rachel Pomerantz Gerber Email: [email protected] Tel: +972-52-3632185

AI Terminal

Evogene Ltd.

6785_rns_2023-05-09_79f70dde-8840-436b-9cf2-4aba4c6111f2.pdf